Search results
Results from the WOW.Com Content Network
Koçak-19 Inaktif Adjuvanlı COVID-19 vaccine Kocak Farma Turkey Inactivated SARS‑CoV‑2: Phase I (38) [231] Phase 1 Study for the Determination of Safety and Immunogenicity of Different Strengths of Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine, Given Twice Intramuscularly to Healthy Volunteers, in a Placebo Controlled Study Design.
The WHO has developed a multinational coalition of vaccine scientists defining a Global Target Product Profile (TPP) for COVID-19, identifying favorable attributes of safe and effective vaccines under two broad categories: "vaccines for the long-term protection of people at higher risk of COVID-19, such as healthcare workers", and other ...
The UNESCO study of publication trends in 193 countries on the topic of new or re-emerging viruses that can infect humans covered the period from 2011 to 2019 and now provides an overview of the state of research prior to the COVID-19 pandemic. Global output on this broad topic increased by only 2% per year between 2011 and 2019, slower than ...
Today, a significant proportion of vaccines against viral diseases are created using nanotechnology. Solid lipid nanoparticles represent a novel delivery system for some vaccines against SARS-CoV-2 (the virus that causes COVID-19). [60] In recent decades, nanosized adjuvants have been widely used to enhance immune responses to targeted vaccine ...
The Canadian government announced CA$275 million in funding for 96 research projects on medical countermeasures against COVID-19, including numerous vaccine candidates at Canadian universities, [179] [180] with plans to establish a "vaccine bank" of new vaccines for implementation if another COVID-19 outbreak occurs.
[2] [3] [8] Volunteering for a vaccine challenge study during the COVID-19 pandemic is likened to the emergency service of healthcare personnel for COVID-19-infected people, firefighters, or organ donors. [2] [3] Human SARS-CoV-2 challenge studies have also been conducted to investigate the viral infection and immune response kinetics in COVID-19.
ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [2] [3] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
A study published in October 2020, screening those drugs approved by the US Food and Drug Administration (FDA) which target SARS-CoV-2 spike (S) protein proposed that the current unbalanced combination formula of lopinavir might in fact interfere with the ritonavir's blocking activity on the receptor binding domain-human angiotensin converting ...